59 studies found for:    cabozantinib
Show Display Options
Rank Status Study
1 Recruiting Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +)
Conditions: NF1;   Neurofibromatosis;   Plexiform Neurofibromas
Intervention: Drug: Cabozantinib
2 Recruiting A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Condition: Prostate Cancer
Intervention: Drug: Cabozantinib
3 Recruiting A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Conditions: Bile Duct Cancer;   Intrahepatic Cholangiocarcinoma;   Cholangiocarcinoma of the Extrahepatic Bile Duct
Intervention: Drug: Cabozantinib
4 Recruiting Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
Condition: Prostate Cancer Metastatic
Intervention: Drug: Cabozantinib
5 Recruiting Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: Panitumumab;   Drug: Cabozantinib
6 Active, not recruiting Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
Conditions: Solid Tumors;   Cancer;   NSCLC
Interventions: Drug: cabozantinib capsules;   Drug: cabozantinib tablets
7 Recruiting Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Conditions: Recurrent Melanoma;   Recurrent Thyroid Cancer;   Thyroid Gland Medullary Carcinoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate;   Other: pharmacological study;   Other: laboratory biomarker analysis
8 Recruiting Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Condition: Hepatocellular Carcinoma
Interventions: Drug: Cabozantinib (XL184);   Drug: Placebo
9 Active, not recruiting Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Conditions: Solid Tumors;   Cancer
Interventions: Drug: XL184;   Drug: Placebo
10 Recruiting Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
Conditions: HIV Infection;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Active, not recruiting Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: cabozantinib-s-malate;   Other: laboratory biomarker analysis
12 Recruiting Cabozantinib in Advanced Solid Malignancies
Conditions: Lung Cancer;   Solid Tumor (Not Breast or Prostate Cancers)
Intervention: Drug: Cabozantinib
13 Active, not recruiting Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
Conditions: Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma
Interventions: Drug: XL184;   Drug: temozolomide;   Radiation: Radiation Therapy
14 Recruiting A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: CABOZANTINIB;   Drug: gemcitabine
15 Recruiting Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Cabozantinib;   Drug: Androgen Ablation Therapy
16 Recruiting Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Intervention: Drug: Cabozantinib (XL184)
17 Not yet recruiting A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
Condition: Medullary Thyroid Cancer
Interventions: Drug: Cabozantinib (XL184) 140 mg;   Drug: Cabozantinib (XL184) lower dose;   Drug: Placebo tablet;   Drug: Placebo capsule
18 Completed Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan
Condition: Neoplasms
Intervention: Drug: BMS-907351 (XL184)
19 Recruiting Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Conditions: Insular Thyroid Cancer;   Recurrent Thyroid Cancer;   Stage I Follicular Thyroid Cancer;   Stage I Papillary Thyroid Cancer;   Stage II Follicular Thyroid Cancer;   Stage II Papillary Thyroid Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer
Interventions: Drug: cabozantinib-s-malate;   Other: laboratory biomarker analysis
20 Recruiting XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease
Condition: Multiple Myeloma
Intervention: Drug: Cabozantinib

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years